Erratum: Disruption of Myc-Max Heterodimerization with Improved Cell-Penetrating Analogs of the Small Molecule 10074-G5

Huabo Wang; Jay Chauhan; Angela Hu; Kelsey Pendleton; Jeremy L. Yap; Philip E. Sabato; Jace W. Jones; Mariarita Perri; Jianshi Yu; Erika Cione; Maureen A. Kane; Steven Fletcher; Edward V. Prochownik

doi:10.18632/oncotarget.26241

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Errata:

Erratum: Disruption of Myc-Max Heterodimerization with Improved Cell-Penetrating Analogs of the Small Molecule 10074-G5

PDF | How to cite

Oncotarget. 2018; 9:35196-35196. https://doi.org/10.18632/oncotarget.26241

Metrics: PDF 1201 views | ?

Huabo Wang¹, Jay Chauhan², Angela Hu¹, Kelsey Pendleton¹, Jeremy L. Yap², Philip E. Sabato³, Jace W. Jones², Mariarita Perri⁴, Jianshi Yu², Erika Cione⁴, Maureen A. Kane^2,5, Steven Fletcher^2,5 and Edward V. Prochownik^1,6,7

¹ Section of Hematology/Oncology, Children’s Hospital of Pittsburgh of UPMC
² Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD, USA
³ PharmD Program, University of Maryland School of Pharmacy, Baltimore, MD, USA
⁴ Department of Pharmaco-Biology, University of Calabria, Rende (CS), Italy
⁵ University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, USA
⁶ Department of Microbiology and Molecular Genetics, The University of Pittsburgh School of Medicine
⁷ The University of Pittsburgh Cancer Institute, Pittsburgh, PA

Published: October 12, 2018

This article has been corrected: During production, the ending page number for this article was listed incorrectly. The page count has now been adjusted to show the proper pagination.

Original article: Oncotarget. 2013; 4:936-947. DOI: https://doi.org/10.18632/oncotarget.1108.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26241

Publication Alerts

Errata:

Erratum: Disruption of Myc-Max Heterodimerization with Improved Cell-Penetrating Analogs of the Small Molecule 10074-G5